Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Magnetic resonance imaging of the human ferritin heavy chain reporter gene carried by dendrimer-entrapped gold nanoparticles
January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative
Chen L, Shi X-J, Liu H, Mao X, Gui L-N, Wang H, et al
[1] [3] However, the gastrointestinal effects of these drugsincluding nausea, vomiting, diarrhea, and constipationcan potentially affect nutrient absorption and electrolyte balance
Upon hepatocyte death, they release P2Y14 ligands that are concentrated in HSCs (Peiseler et al., 2022)
US$ 23.32
US$ 22.68
US$ 26.43
US$ 25.01
